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Abstract 
This paper reviews the evolution of hormone delivery systems and discusses future technological trends in 
the field. From intravaginal devices to recent advances in nano and microcapsules will be reviewed. The 
description of delivery systems manufacture processes, their advantages and disadvantages and the 
reasons for their success and eventual decline will be described. The increment of the Global demand of 
animal products, the need for cost reduction, the limited fertile land, the competition with agriculture and 
the preservation of biodiversity were identified as the driving forces for technological evolution of 
hormone delivery systems. Micro and nanoencapsulation processes, biomaterials and subcutaneous 
delivery routes dominate actual research topics. Neuronal targeted drugs administrated through non-
invasive routes are speculated as one of the most promising future drug delivery system for estrous 
synchronization in livestock. 
Keywords: Drug Delivery, Animal Reproduction, Artificial Insemination, Ovulation, 
Microtechnology, Livestock 
 
Introduction 
The production of animal products is a key issue for mankind in the XXI century. The way to 
reproduce animals deals with a number of topics related to technical, biological, economical, 
social, environmental, regulatory, ethical and health aspects. The analysis of past and actual 
hormone delivery systems permits to visualize the nature of future technologies. This paper 
serves as an up-to-date source of information for those involved in farm animal reproduction 
activities, may facilitate the understanding of driving forces for research and may prepare 
production units, education programs, regulatory agencies and public opinion to accept new 
technologies in estrous synchronization. 
The demand of animal products is expected to experience a great increase during the XXI 
century. The offer of animal products could be increased by three basic strategies: increasing the 
number of animals; increasing the animal productivity through drug enhanced metabolism and 
increasing the animal productivity through genetic improvement. The first option is not long 
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term sustainable. The limited amount of fertile land, the competition with agricultural and urban 
spaces and the everyday more restricted access to new land in detriment of biodiversity and 
natural forests can be mentioned as the main reasons for such statement. The second option is 
under discussion. On the one hand, the United States policy is rather permissive in the use of 
drugs such as anabolic steroids and growth promoting hormones for the acceleration of the 
animal metabolism. On the other hand, the European policy is quite restrictive in altering the 
animal metabolism. The policy of Latin American countries tends to follow the European 
normative since the European Community is the main exportation market of the Latin American 
livestock production. Finally, the third option seems to be reasonable without restrictions except 
those implying ethical issues related to gene modification through gene engineering techniques. 
Genetic breed improvement through selective crossbreed has been used by mankind during 
centuries. The development of artificial insemination (AI) techniques accelerated the breed 
improvement process while keeping its essence as an ethically right procedure. 
Globally, near 20% of the bovine breeders, 110.5 million animals per year are artificially 
inseminated. Far Orient and Oceania, Europe, North America and South America register 58.2, 
37.7, 11.2 and 1.4 million operations annually, respectively (Thibier and Wagner, 2002). 
The artificial induction and synchronization of estrus in production animals is critical to ensure a 
positive balance of the cost-benefit equation of the AI related activities. The costs related to the 
selection and extraction of quality semen, the conservation and logistics of semen, the detection 
of estrus and the insemination of animals are compensated only if a large number of animals in 
estrous are simultaneously treated.  
Hormone treatment is the usual method to induce estrus and ovulation in production animals. 
The administration of hormones must be very precise. The bioavailability of the hormones 
should be keep within strict levels to induce estrus and ovulation without negative side effects.  
The controlled hormone release is a current technological challenge. A multitude of disciplines 
such as materials science, animal physiology, production processes, application techniques and 
farm supply logistics among others converge in the development of hormone delivery systems 
(HDS). Several HDS have been developed for the controlled release of one or more hormones 
according to defined profiles. These HDS have evolved during more than 40 years according to 
the technological advance of a multitude of disciplines, sometimes not directly related to 
reproductive veterinary. Nowadays, HDS represent about 15% of the global market of veterinary 
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products (Evans, 2010). 
This paper reviews the technological evolution of HDS for the artificial induction and 
synchronization of estrus and ovulation in cattle. Moreover, a brief explanation of the driving 
forces for the development of the time ago called “new” concepts and associated technologies 
and the reasons of their decline, obsolescence and replacement by other technology is included. 
Finally, the future technological trends based on the recent advances on biomaterials and 
nanotechnology will be discussed. 
The problem of animal reproduction 
Globally more than 90% of the animal reproduction is carried out without human intervention 
(Barbosa and Machado, 2008). The reason for such situation is the difficulty to control the estrus 
cycle and to detect ovulation in the animals as preliminary condition for AI. Normally, the fertile 
period of bovine breeders ranges between 24 to 48 h. Besides, animals from the same herd 
ovulate several weeks apart (Ball and Peters, 2004). The very short fertile period and the high 
temporal dispersion of ovulation within the herds implies that the staff responsible for carrying 
out the insemination should be present almost every day at the field to run a detailed examination 
of each animal, identify those in the fertile period and eventually inseminate them. In addition, 
the total cost of the operation is increased by the consequences of the poor accessibility to the 
herds due to the large distances between urban centers and livestock locations, the precarious 
state of rural roads, the strict requirements of the logistics of semen and the complication of 
activities carried out in open field conditions. Finally, the animal reproduction assisted by AI 
became unprofitable for the common livestock producer. 
The ultimate consequences of this situation are a significant drawback in the increase of the 
genetic charge of the herds and associated loss of productivity. Moreover, the profitability of the 
livestock space diminishes as a consequence of large periods for deliveries, awkwardness for the 
assistance and control of calves of different ages, loss of efficiency of vaccination and feeding 
programs and the low performance of the involved staff. 
The main advantages that would bring the synchronization of estrus in livestock are: a substantial 
increase in the rate of genetic breed and herds improvement, the concentration of animals in 
estrus in a short period, the rationalization of AI, the concentration and reduction of the calving 
period, the streamlining of vaccination programs, the improvement of feeding programs 
according to the season and the age and breed of the animals, a greater ease in implementing 
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zootechnical tests to determine trading parameters, simpler traceability of animals and better 
management and logistics of animals (Becaluba, 2006). 
Developed technologies and drug delivery routes 
Several technologies have been developed with the aim of controlling the estrus cycle in cattle. 
They all imply the administration of drugs and hormones with different functions in the 
reproductive metabolism of the animals. Several polymeric matrices have been used for the 
sustained release of drugs and hormones in order to obtain well determined drug concentration 
and profiles during a specific time. Matrices have been designed in various shapes and can be 
placed in different sites of the animal to activate its function. According to the application site, 
the matrices can be classified in four categories: intravaginal delivery systems, subcutaneous 
delivery systems, respiratory route delivery systems and dermal delivery systems. 
Intravaginal delivery systems 
Intravaginal devices were developed in the 1970’s by taking advantage of the possibilities 
offered by extrusion, injection molding and lamination of thermoplastics. They are the most 
currently applied HDS. A brief description of the devices and their manufacturing processes is 
presented below. 
The Progesterone Releasing Intravaginal Device (PRID) comprises 1-3 g of micronized 
progesterone, uniformly suspended in a silicone rubber matrix which is cured onto a stainless 
steel spiral. A progesterone mixture suspended in liquid silicone rubber is injection molded 
around a 3.5x28.5x0.1 cm3 stainless steel plate. Then, the silicone matrix is cured inside the 
mold, so that it becomes an elastic semisolid. It is removed from the mold and formed into a coil 
with a diameter of approximately 4 cm and a length of approximately 12 cm (Rathbone et al, 
1997). Figure 1 shows a scheme of a PRID. The release rate of progesterone depends almost 
exclusively on the contact area between the device and the vaginal epithelium of the host animal. 
The retention rate of these devices is usually very high, usually over 95%. Although, it has been 
initially designed for cows, with minor modifications it can be also used in mares (Rathbone et 
al, 1997). 
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Figure 1 
Controlled Internal Drug Release (CIDR) devices are made of a “T” or “Y” shaped nylon spine 
manufactured by injection on which it is deposited, by automated injection molding, a layer of 
0.9-5.0 mm of silicone rubber impregnated with 1.9 g of micronized progesterone (Macmillan 
and Peterson, 1993). Figure 2 shows the scheme of a CIDR. The device has two wings used to 
exert a small pressure in the walls of the vagina in order to ensure its retention. Usually, retention 
rates in cows are over 95%, but they are lower in case of mares and buffalos. The great 
technological improvement of the CIDR is the replacement of the metallic soul and the spring 
shape of the PRID by a cheaper and more flexible nylon soul and a more anatomic Y shape, 
respectively. 
 
Figure 2 
Numerous sponge devices have been developed and studied academically. However, few of them 
have been produced in mass and converted in commercially available products. Its application is 
limited almost exclusively to sheep. The sponges present different lengths, diameters, densities, 
porosities and consistence. Generally, they are produced by processes similar to those used to 
obtain polyurethane foam. In fact, polyurethane foam is the most extended material used for the 
manufacturing of sponge based HDS. Those processes comprise the dissolution of the polymer in 
a low boiling point liquid solvent. Then, the solvent is rapidly volatilized obtaining a sponge of 
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the polymer previously dissolved. The intravaginal device is obtained through the pulverization 
of a hormone solution in a volatile solvent, such as alcohol (Carrick and Shelton, 1967) or 
acetone (Davis et al, 1983), on the surface of the sponge. This method has been used to obtain 
sponges impregnated with progesterone (Scanlon et al, 1971) and estradiol (Davis et al, 1983), 
among others hormones with proven activity in the regulation of the reproductive cycle. Once 
the sponges have been impregnated, the solvent evaporates and the hormones remain finely 
deposited on the large surface of the sponges (Hale and Symington, 1969). An alternative 
procedure is the immersion of the base sponge in a bath of hormone solution. Then, the sponge is 
removed from the bath and the solvent is vaporized, obtaining a hormone dispersion over the 
sponge surface (Shimizu et al, 1967). It is usual the addition of antibiotics to these devices 
because its greater specific surface increase the possibility of microbial colonization. Figure 3 
shows a basic scheme of this sponge-like intravaginal device. 
 
Figure 3 
The Intravaginal Application System (INVAS) comprises a “T”-shaped flexible polypropylene 
structure with a length of approximately 14 cm, covered with a progesterone-impregnated 
silicone rubber skin. Its shape is similar to the CIDR. The progesterone addition to the silicone 
matrix is done through a lamination and milling process, similar to that used in the incorporation 
of sulfur and black carbon to the rubber in tire production. In this case, the material is treated as a 
paste. This paste is laminated and cut in a T-shape. A silicone-polypropylene-silicone sandwich 
is obtained inside a mold. The mold is closed and heated to cure the silicone and seal the 
sandwich structure (Hornykiewytsch, 1988). This method allows the use of plastics of lower 
melting point than in the CIDR case and the progesterone does not change its crystalline 
structure during the process (Hiller and Hornykiewytsch, 1995). 
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The Ring-like Intravaginal Device was extensively investigated but with no commercial success. 
It comprises a plastic or steel ring covered with a hormone-impregnated silicone rubber skin. The 
major disadvantage of this device is its poor retention in the vagina, which in no case has 
exceeded 3 days (Roche, 1976). Figure 4 shows the diagram of a ring-like intravaginal device. 
 
Figure 4 
The Rajamahendran intravaginal device is obtained from two silicone tubes with a length of 
approximately 20 cm, an inside diameter of 0.8 cm and an outside diameter of 1.3 cm. A diethyl 
ether solution of progesterone is poured in the tubes, then the solvent is vaporized and the tubes 
are sealed. An estradiol paste is dispersed in a layer around the ends of the silicone tubes. 
Finally, both tubes are centrally tied together forming a cross. Strings can be fastened to the 
tubes to facilitate the removal from the vagina (Rajamahendran et al, 1982). Figure 5 shows a 
scheme of this device. 
 
Figure 5 
The Intelligent Breeding Device (IBD) allows the release of different hormones such as 
progesterone, prostaglandin, and estradiol with rates perfectly defined at specific times. This 
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device comprises a head connected to a container. The head has tubular flexible arms that 
facilitate the introduction of the device, its retention in the vagina and the hormone release. The 
container is a hermetically-closed, rigid plastic tube with a length of approximately 12 cm and a 
diameter of 4 cm. The controlling chip, the plunger micropumps, the hormone reservoirs and the 
batteries are arranged inside the container. The chip and the micropumps are programmed in 
order to control the rates and times of release of the different hormones (Jellie, 2002). Figure 6 
shows the external view of an IBD. This device was discontinued due to its complexity and 
disappointing field trials. 
 
Figure 6 
All the intravaginal devices intend to release in a sustained way, one or various hormones with 
the aim of control the estrus cycle of the animal. These devices must be introduced in the animal 
vagina to activate their function. Their big size and geometrical complexity make difficult its 
production, storage and transport. Their use usually involves the following steps: 
1) Immobilize the animal so as to have access to the rear. This task is not always easy to 
accomplish on the precariousness of the country.  
2) Clean up the vaginal area of the animal to minimize the risk of infection. It is essential to use 
gloves, cleaning agents, disinfectants and especially large amount of clean water under certain 
pressure. It is important to mention that these requirements are many times difficult to 
accomplish in the precarious conditions of the country. 
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3) Carefully insert the device into the vaginal cavity of the animal, avoiding any contact that 
could lead to transfer some hormone from the device surface to the skin of the operator. It 
implies the mandatory use of gloves. The gloves must be replaced from animal to animal to 
avoid the eventual propagation of venereal diseases through the herd. The use of gloves has 
important economic consequences due to the costs of related logistics and final disposal actions. 
The insertion of intravaginal devices should be performed by trained and skilled personal, which 
means an extra cost in education and training. The serial production of intravaginal devices 
makes virtually impossible to manufacture customized devices. Therefore, the devices are 
fabricated with a dosage, size and shape according to the average animal. Thus, there is always a 
risk of under or over dosage because the optimal dose may vary from animal to animal. In 
addition, the vaginal anatomy varies greatly in size, physical consistency and specific 
particularities, depending on the animal size, breed, age, previous deliveries, etc. Consequently, 
the device may not enter or come loose falling out the vagina.  
4) The device must be removed from the vagina after a 7-10 days period. The animal must be 
immobilized and hygienized again. The device should be taken out by qualified personnel, with 
appropriate security conditions and the mandatory use of gloves. Commonly, the exhausted 
devices may present a hormone residue of 40-60 wt% and the propagation of venereal diseases is 
always present. 
5) Finally, the exhausted devices and used gloves must be compulsory burned or buried as final 
disposition act to prevent any future accidental contact with the human skin. 
It is common that the use of intravaginal devices is accompanied with the intramuscular injection 
of supplementary hormones. The following describes a protocol for the use of a commercially 
available intravaginal device. Day 0: immobilize the animal, clean the vaginal area, insert the 
intravaginal device, and inject 2 mg of estradiol benzoate intramuscularly. Day 8: immobilize the 
animal, clean the vaginal area, remove the device, and inject a dose of prostaglandin. Day 9: 
inject estradiol benzoate; 1 mg in cows and 0.75 mg in heifers. Day 10: detect heat and 
inseminate or use the fixed time AI (Pfizer Sanidad Animal, 2012). 
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From the beginning of the treatment to the insemination day, each animal was handled 10 times. 
Thus, the final cost of the operation results quite high and the logistics and coordination of 
specialized personnel involved is very complex. 
Herein lays the reasons for the developing of subcutaneous delivery systems. 
Subcutaneous delivery systems 
Two big fields can be distinguished in this route of hormone administration: implantable and 
injectable systems. The implantable systems generally require a surgery to access the 
subcutaneous tissues and implant there the delivery system. The injectable systems access these 
tissues through the use of veterinary needles. 
The HDS implantable under the skin was the first subcutaneous delivery system to be developed. 
These systems comprise tubes (Short et al, 1976) or disks (Scanlon et al, 1971) made of silicone 
or other biocompatible polymers, not necessarily biodegradable, that have been loaded in some 
way with progesterone or another hormone. These systems are implanted under the skin of the 
animal with a small surgery in order to allow the release of the hormone directly to the animal's 
body. In these cases the quality and the purity of the hormone and the size and the shape of the 
implant have crucial importance. The effectiveness of these delivery systems is generally pretty 
good. However, the dosage problem remains because the implants are manufactured with a 
unique hormonal load. In some cases, additional surgery is necessary for the removal of 
exhausted systems. The large size of the implants, the need to immobilize the animal for the 
surgery, the need for proper aseptic conditions in the surgery, and eventually the double 
sequence of tasks related to the removal of the exhausted implant lead to serious doubts about the 
feasibility of implementing these types of HDS.  
The subcutaneous delivery systems implanted in the ear were designed as a way to facilitate the 
operations of implanting and removal of the devices. Several types of ear implants and its 
implanting devices have been developed at commercial scale. These implants are polyurethane 
or silicone tubes with at length of 20 mm and a diameter of 3 mm. They contain between 5-15 
mg of hormones homogeneously distributed in the polymer matrix (Chien and Lau, 1976)
. 
The 
implants are stored with protective sheaths. They are put in the implanting device and introduced 
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into the animal’s ear with relative ease. The technique greatly simplifies the surgery work. The 
removal of the implant is made with a small incision. However, as in previous cases, the 
hormone residue is between 50 and 65 % of the initial load (Moseley et al, 1979), so the dosage 
problem is still remaining and it has also been proved that the hormone release rate is not 
constant during the treatment (Kesler et al, 1995). The Microsealed Drug Delivery (MDD) 
technology was developed as an attempt to keep constant release rate. These types of HDS are 
similar to the previous one being the only difference that the hormone is contained in 
polyethylene glycol reservoirs dispersed in the polymer matrix (Chien, 1982). Figure 7 shows a 
scheme of the application of an ear-implanted delivery system. 
 
Figure 7 
The injectable systems appeared in the last decade of the XX century, as an alternative to 
eliminate the surgery needed to implant and remove the implantable delivery systems and the 
dosage problem. An injection does not need rigorous aseptic conditions; it is simpler and quicker 
that an implant and it has the possibility of varying the doses by adjusting the injected volume, 
without the need for highly qualified personnel. Once injected, it is not possible to remove the 
delivery system, so it is necessary to design it with biocompatible and biodegradable matrices 
capable to release the hormones with a zero order pattern during a period of 7-10 days followed 
by a sudden decay. The injectable delivery systems are classified in three categories: transdepot, 
preformed systems and in situ formed systems. 
The transdepot systems comprise liquid hormonal solutions, with variable viscosity, where the 
hormone is dispersed or in solution. The system is always liquid when injected. Once injected, 
the system becomes a semisolid by some physical-chemical change induced by the environment 
of the injection site. This technology was initially developed for human medicine (Tsung and 
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Burgess, 2012). Then, it evolved to veterinary medicine. In most cases, the simple transfer of an 
application in humans to animals results with some technical success but it is highly unfeasible 
from an economic point of view. The so-called thermoplastic pastes are injected as a molten 
liquid at a temperature higher than those of the injection site. Once injected, the liquid is cooled 
to the animal's body temperature, forming a semisolid depot and entrapping the hormonal load 
(Bezwada, 1995). The hormonal load is released to the environment according to the structure 
and characteristics of the depot. The most used materials for the manufacturing of these systems 
are biodegradable, biocompatible, low molecular weight polymers and copolymers derived from 
the lactic acid, glycolic acid, caprolactone, trimethylene carbonate, dioxanone, and ortho esters 
(Bezwada et al, 1997; Einmahl et al, 2001). However, it is important to note that the melting 
points of these polymers are above 60°C, so its injection could be very painful and produce 
necrosis and crusts in the adjacent zone (Liu and Wilson, 1998). On the other hand, various 
geometric shapes could be adopted by the depots during their injection, from beads to tree or 
spider shapes. Different shapes result in a wide dispersion of the release rates due to the random 
and uncontrollable variation of the contact area. Relatively low release rates are also observed in 
these systems (Dordunoo et al, 1997). Another transdepot injectable system is the in situ cross-
linking type. A liquid solution is prepared containing monomers, polymers, the cross-linking 
agent and the drugs, which could be dispersed or dissolved. This solution is injected into the 
animal. Once injected, the cross-linking agent is activated by some physical-chemical stimuli, 
polymerizing and linking polymeric chains, forming a semisolid with the drug load trapped 
inside (Dunn et al, 1994). The initiators must be added to the solution some seconds before the 
injection to avoid cross-linking in the syringe. The toxicity of the monomers and cross-linking 
agents, the ability to inhibit the reaction of physiological conditions and body fluids, and the 
temperature rise due to highly exothermic reaction of polymerization and curing that may 
seriously affect surrounding tissues can be mentioned as limiting facts in the application of such 
systems (Peter et al, 1997; Zhao et al, 2000). The most recent transdepot systems are the so-
called ion-induced gelation systems. They comprise biopolymers that are capable of gelling in 
the presence of polyvalent cations. Alginate and albumin in combination with calcium are the 
most studied (Viegas et al, 1994; Cui and Messersmith, 1998). Finally, it must be mentioned the 
injectable delivery systems formed by polymer precipitation. In these cases, a mixture is 
prepared containing a biodegradable and biocompatible polymer, generally derived from lactic 
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acid, glycolic acid and caprolactone, a biocompatible and bioassimilable solvent, such as 
pyrrolidone and dimethyl sulfoxide, and the hormone load. This mixture must be homogeneous 
and stable while stored. Once injected, the precipitation of the polymer is induced in the injection 
site, forming a solid or semisolid structure with the drug trapped inside (Dunn et al, 1990). The 
hormone is released to the environment according to the characteristics of the formed structure. 
Generally, the polymer precipitates by solvent removal (Shah et al, 1993), temperature changes 
(Jeong et al, 2000) or pH changes (Siegel et al, 1988). The addition of surfactants allows 
controlling the polymer precipitation in form of massive elements, sponges, particles and 
microparticles. The limitation of such procedure is the high level of drug release just before and 
in the early stages of the polymer precipitation (Shively et al, 1995; B.L. Chandrashekar et al, 
2000). This causes serious irritations in the adjacent tissues and can even be toxic to the host 
organism. Besides, most of the solvents and eventually surfactants used in the formulation of the 
depots are toxic, potentially hemolytic, with necrotic power and can damage muscle activity (G. 
Chandrashekar and Udupa, 1996). 
The situation previously discussed and the recent development of micro- and nanotechnologies 
are the driving forces for the development of delivery systems comprising microparticles. 
Microparticle is a general term used to identify microspheres, microbeads and microcapsules. In 
the context of veterinarian products, the word micro usually refers to systems able to flow and be 
injected through veterinary needles. The method consists in preparing microparticles, generally 
microspheres. The hormonal load is trapped or encapsulated during such process. These 
microparticles are dispersed in a carrier liquid and injected into the animal. There are no less 
than 18 techniques to obtain microparticles, of which 11 would be appropriate to obtain 
preformed, hormone loaded microparticles. Each technique has particular advantages and 
disadvantages. The main challenge is to select the most appropriated technique for a given set of 
load, material and application. Following, it is presented a brief description of each technique. 
The emulsion method consists in the dispersion of two immiscible phases, being the drug soluble 
just in the discontinuous phase. Subsequently, the continuous phase is removed by spray drying 
leaving the drug encapsulated in the dispersed phase (Frangione-Beebe et al, 2001; Benita and 
Tamilvanan, 2006). 
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The internal gelation technique comprises the dissolution of the drug and a polysaccharide in 
water. This solution is dispersed in an immiscible oil phase containing a polysaccharide gelling 
precursor dissolved. The addition of a destabilizing agent, generally Ca2+, induces the gelation 
of the dispersed phase, trapping the drug in this matrix (Poncelet, 2001). 
The encapsulation method by phase separation forms a drug suspension using a hydrophilic 
polymer. Then, the polymer precipitation is inducted and the drug remains trapped inside the 
precipitated microparticles (Bachtsi et al, 1996; Lamprecht et al, 2000). 
The interfacial polymerization method consists in dispersing or dissolving the drug load in a 
monomer solution, which is then dispersed in an oil phase containing the polymerization 
initiator. The polymerization occurs in the oil interface, leaving the content encapsulated inside 
the monomeric phase (Levy and Andry, 1991; Kulkarni et al, 2000). 
The atomization method consists in dispersing a polymer/drug solution in a gas phase with 
sudden evaporation of the solvent. This process leaves the drug trapped in a polymer matrix 
(Abraham et al, 1996). 
The desolvation technique comprises the dissolution of a drug and a wall-forming material in a 
small quantity of solvent. This solution is then extruded or dispersed in a medium with excess of 
non-solvent liquids. The non-solvent desolvates the solution leaving the content trapped in a 
matrix constituted by the wall-forming material (Lamprecht et al, 2000). 
The centrifugal extrusion method consists in pumping a solution of the wall-forming material 
and a solution or dispersion of the drug through a dual-head rotor. The drug solution passes 
through the internal head and the wall-forming material solution passes through the external 
head. The centrifugal force breaks the stream forming drops of drug covered by the wall-forming 
material. These drops become capsules upon contact with a solution of the gelling agent of the 
wall-forming material (Gibbs et al, 1999). 
The rotating disk atomization method consists in dispersing a drug/wall-forming material 
solution in a liquid film over a rotating disk. When the fluid reaches the edge of the disk is 
ejected as droplets. These droplets become capsules upon contact with a hardening solution 
(Ogbonna et al, 1989); Senuma et al, 2000). 
In the jet cutting method the drug/wall-forming material solution is passed through a hole 
forming a continuous stream which is cut by a rotor with multiple blades. The drops will then fall 
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into a gellant solution to form the capsules (Prüße et al, 1998). 
Finally, in the encapsulation by electrostatic dripping or by vibrating extrusion, the drug/wall-
forming material solution passes through needles. Each forming droplet in the tip of the needle is 
pulled from it by means of an electrostatic force or by mechanical vibration as appropriate (Hulst 
et al, 1985; Bugarski et al, 1994; Hallé et al, 1994). 
Two or more of these techniques could be combined to produce multilayer microcapsules. In 
general, the most appropriated techniques for producing large volumes such as emulsion or 
atomization encapsulation, give very small particles with wide dispersion of sizes and properties. 
By contrast, techniques that allows precise control of size, size distribution and particle 
properties, have much lower production volumes and are not ease to scale-up. 
Delivery systems by respiratory route 
A recent way of induction of estrus in programmed reproduction of animals is the controlled 
pheromone delivery by respiratory route. The technique is very recent and still not fully 
developed. It comprises the microencapsulation by atomization of very small doses of 
pheromones that are then administered to animals by inhalation using a single dose. The 
activation of the animal's hormonal metabolism is the great advantage of this technique. 
Pheromones have the ability to wake up the hormone production system through very specific 
actions in hypothalamic centers
 
(Whitten, 1999; Rekwot et al, 2001; Villeneuve, 2001). Another 
developing technique is the use of free or encapsulated progesterone for nasal administration. In 
the first case, progesterone microcrystals, obtained by antisolvent or combined antisolvent and 
cooling crystallization (Ragab et al, 2010), or progesterone suspensions in isotonic solutions of 
polyethyleneglycol are used (Corbo et al, 1988), while in the second case ciclodextrins are the 
most employed materials for the encapsulation of progesterone in order to enhance the solubility 
and absorption of the steroid (Van den Berg et al, 2004; Rathnam et al, 2008). The potential of 
this technology is to avoid the first-pass metabolism, increasing therefore the hormone half-life. 
However, the use of nasal spray devices is expensive and difficult to apply to large herds in open 
field. 
Delivery systems by dermal route 
The skin is one of the most important organs of the body. It is a complex membrane, comprising 
three layers: the dermis, the epidermis and the outermost layer, the stratum corneum. The latter 
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acts as a barrier towards the penetration of different objects and molecules, and controls the 
permeation and release of active compounds. Several veterinary drugs are being formulated into 
topical products. Various approaches have been studied to develop dermal formulations. One 
approach includes the development of emulsions and microemulsions containing a continuous 
aqueous phase, a dispersed oil phase with the lipophilic hormone and surfactants. These 
formulations usually includes skin permeation enhancers, such as surfactants, cyclodextrins, fatty 
acids, chitosan derivatives and chelators. The second approach consists in the development of 
membrane reservoirs hydrogels containing the hormone. In this case, different polymers have 
been used to obtain a zero order release, such as chitosan derivatives, polyacrylic acid 
derivatives, cellulose derivatives, etc. Transdermal patches are divided in matrix type, which 
contain an additional adhesive layer or the matrix is self-adhesive, and membrane controlling 
type consisting in a rate controlling membrane of poly(ethylenvinylacetate) or polyehtylene. In 
these cases the drug is dissolved or suspended in a lipophilic membrane (Valenta and Auner, 
2004). Recently, liposomes (Biruss and Valenta, 2006) and polymer nanoparticles (Tomoda et al, 
2012) have been investigated for the transdermal delivery of steroids. These systems overcome 
the first-pass metabolism and can deliver a constant dose of drugs for long time (Prausnitz and 
Langer, 2008). Despite the fact that the skin has the same three layers in all the animals of 
interest, there are important specie-specie and specie-climate variations in epidermal anatomy 
and physiology that discourage the extended use of a single transdermal delivery system 
(Monteiro-Riviere, 1990). Besides, the use of permeation enhancers leads to potential skin 
irritation (Jordan et al, 1998). 
Conclusion and future perspective 
The increasing demand for animal products is the main driving force for the improvement of 
animal reproduction programs and techniques. The steady decline in grazing land, either by 
desertification, competition with agriculture, urban and biodiversity reserves, the restrictions 
from health and food safety agencies and the ethical issues involving artificial gene modification 
of animal food products lead the development of natural genetic improvement of farm species by 
cross-breeding programs which lead directly to the development of drug delivery systems for 
control and synchronization of estrus and ovulation cycle, as previous steps for AI. The trend is 
to develop delivery systems more economic, with simple and robust production processes, less 
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invasive, with no long-term effects in animals, ease to apply and dose and secure for those who 
handle it. It has been observed a gap of 30 to 40 years from conception of delivery systems to 
commercially availability. It has also been seen several developments that has never come to 
production and commercialization stages. The explosion of micro- and nanotechnologies 
currently proposed a wide spectrum of techniques. Over time the less efficient will be discarded 
and those with higher yields and lower cost/benefit ratio will be refined. Despite the great efforts 
in the development of more efficient HDS the market is dominated by CIDR type intravaginal 
devices. However, more than 90% of the global animal reproduction business is still waiting for 
a technically efficient and economically profitably new technology for controlled hormone 
delivery. 
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